Followers | 30 |
Posts | 5248 |
Boards Moderated | 0 |
Alias Born | 10/16/2012 |
Wednesday, July 29, 2015 9:02:35 AM
Source: PR Newswire (US)
MARLBOROUGH, Mass., July 29, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology today announced that it will report financial results for the second quarter ended June 30, 2015 on Wednesday, August 12, 2015 after the close of the U.S. financial markets.
A live audio webcast will begin at 4:30 p.m. EDT. The webcast link is available under the "Investors" section of the Company's website, www.rxipharma.com. The event may also be accessed by dialing toll-free in the United States and Canada: +1 888-669-0684. International participants may access the event by dialing: +1 862-225-5361. An archive of the webcast will be available on the company's website approximately two hours after the presentation.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology that address high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and ocular scarring. It also includes an immunomodulator, Samcyprone™, a proprietary topical formulation of diphenylcyclopropenone (DPCP), for the treatment of such disorders as alopecia areata, warts, and cutaneous metastases of melanoma.
RXi's novel, self-delivering RNAi (sd-rxRNA) compounds are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. sd-rxRNAs have been shown, in vitro and in vivo, to achieve efficient spontaneous cellular uptake and potent, long-lasting intracellular activity.
RXI-109, an sd-rxRNA compound, is the Company's first clinical development candidate. RXI-109 silences Connective Tissue Growth Factor (CTGF), which plays a key role in tissue regeneration and repair and is initially being developed to reduce or inhibit scar formation in the skin and in the eye. RXI-109 is currently being evaluated in Phase 2a clinical trials in dermatology. The Company's sd-rxRNA technology platform is broadly protected by multiple issued patents and numerous patent applications.
RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.
Recent PHIO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 09:00:13 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/20/2024 09:03:23 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/20/2024 08:59:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/17/2024 08:45:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/17/2024 01:04:34 PM
- Phio Pharmaceuticals Secures New Investor • GlobeNewswire Inc. • 05/17/2024 01:00:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 01:00:13 PM
- Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 05/16/2024 12:00:00 PM
- Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study • GlobeNewswire Inc. • 05/15/2024 05:00:00 PM
- Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 09:25:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:20:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/08/2024 09:04:03 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/08/2024 09:02:05 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/08/2024 09:00:34 PM
- Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells • GlobeNewswire Inc. • 04/22/2024 05:10:09 PM
- Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 04/16/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- National Spotlight Features Phio’s Innovative RNAi Technology Platform • GlobeNewswire Inc. • 04/03/2024 11:30:00 AM
- Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies • GlobeNewswire Inc. • 03/21/2024 11:30:00 AM
- Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research • GlobeNewswire Inc. • 03/13/2024 06:00:25 PM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM